

Exploring the Intersection: Pain Relief Medication and Antidepressants in Clinical Practice

Sadaf Iqbal¹, Ayesha Saddiqa¹, Madiha Aslam², Sarmad Yousaf¹, Komal Naz¹, Muhammad Kaleem Ullah.^{3*}

Abstract

Depression is not exclusive to any age group, social class, or economic level; in high-, low-, and middle-income countries, its prevalence are 5.5%, 5.5%, and 5.9%, respectively. Pain is the most common physical sign of depression, a complex disorder that affects millions of people worldwide. Although conventional antidepressants have been used for a long time to treat pain associated with depression, new research on these drugs has produced encouraging findings. However, some studies have suggested that due to certain biological, psychological, and environmental factors, women are more likely than males to experience depression (5.1% vs 3.6%). Depression can occur in childhood and adolescence, but it is more common in older adults. On the other hand, stressful life events like losing a job or family member, experiencing financial hardship, or having a chronic illness can often set off depressive episodes. Not everyone exposed to traumatic events early in life reacts to adversity the same way, even though these experiences linked to an increased risk of developing depression in maturity. Actually, The most prevalent physical symptom of depression, a complicated illness that affects millions of people globally, is pain. depression. A common symptom of depression, pain has a substantial negative influence on patients' quality of life and presents significant management issues in the clinical setting. According to epidemiological research, depressive people report pain complaints at a disproportionately high rate, and acute pain is a strong predictor of suicide thoughts and attempts. It implies that it will be critical to show how important these therapies are for treating pain disorders in the future. Translation studies in humans and animals advised to do this, with a focus on comparing phenotypes with the established association between pain and depression and the complex character of this illness. Pain is the most common physical sign of depression, a complex condition that affects millions of people worldwide. Key words: Depression, Prevalence, Epidemiological, Substantial, Disorder.

Introduction

*Author for Correspondence

Muhammad Kaleem Ullah

E-mail: muhammadkaleemullah70@gmail.com

¹Student, Department of Chemistry Government College University Faisalabad Pakistan.

²Student, Department of Chemistry University of Sargodha Pakistan

³Student, Department of Zoology University of Okara Pakistan.

Received Date: May 07, 2024

Accepted Date: June 25, 2024

Published Date: July 12, 2024

Citation: Sadaf Iqbal, Ayesha Saddiqa, Sarmad Yousaf, Komal Naz, Madiha Aslam, Muhammad Kaleem Ullah. Exploring the Intersection: Pain Relief Medication and Antidepressants in Clinical Practice. International Journal of Analytical and Applied Chemistry. 2024; 10(1): 17–20p.

Depression, a multifaceted disorder affecting millions worldwide, often manifests with physical symptoms, prominently pain. While traditional antidepressants have long been prescribed to manage depression-related pain, recent investigations into a typical antidepressants have yielded promising results [1]. Depression is not exclusive to any age group, social class, or economic level; in high-, low-, and middle-income countries, its prevalences are 5.5%, 5.5%, and 5.9%, respectively [2]. However, some studies have suggested that due to certain biological, psychological, and environmental factors, women are more likely than males to experience depression (5.1% vs 3.6%) [3]. Depression can occur in childhood and adolescence, but it is more common

in older adults. Depressive episodes typically start in adolescence (age: <20 years) and can last into adulthood (age: 40 years) [4]. Depression is not limited to any age group, social class, or economic status; its prevalence is 5.5%, 5.5%, and 5.9%, respectively, in high-, low-, and middle-income nations [2]. However, other research indicates that women are more prone than men to experience depression (5.1% vs. 3.6%) because of a number of biological, psychological, and environmental reasons [3]. Although depression can strike at any age, older persons are more likely to experience it. Depressive episodes can extend into adulthood (age: 40 years) and usually begin in childhood (age: <20 years) [4,6]. Individuals who have persistent pain may experience psychological disorders and emotional issues. Research has shown that concomitant psychiatric problems affect over 67% of individuals with chronic pain; of these, 35% exhibit symptoms of sadness and 22% display neurotic disorders [78]. According to a research, between 75 and 80 percent of individuals with depression report having ongoing pain, particularly headache, stomach, neck, or lower back discomfort. Furthermore, research has shown that depression affects 20%–40% of fibromyalgia patients, while mood disorders are connected with 17.5% of patients who have persistent spine pain [9]. According to this research, depression is more likely to occur in people who experience chronic pain. Lastly, research has shown that 20% of individuals with chronic pain have suicidal thoughts and that 5%–14% of them had attempted suicide at some point in their lives [10]. Depressed patients presenting with pain as a symptom have a worse prognosis [11]. These newer medications not only alleviate psychological distress but also demonstrate efficacy in ameliorating physical discomfort associated with depression [12]. Notably, research reveals that patients suffering from major depressive disorders concurrently experience relief from low back pain upon administration of certain antidepressants, with negligible impact on psychological symptoms. This intriguing finding underscores the potential of newer antidepressants to directly target the psychological underpinnings of pain, presenting a novel therapeutic approach that circumvents the need for analgesics, which may exacerbate depressive symptoms and pose risks of abuse in exposed populations.

Pain, a ubiquitous symptom in depression, significantly impacts patients' quality of life and poses considerable challenges in clinical management. Epidemiological studies indicate a disproportionate prevalence of pain-related complaints among depressed individuals, with severe pain serving as a significant predictor of suicidal ideation and attempts [13]. Furthermore, the approval of morphine for dysphoric disorder underscores the intricate interplay between pain and mood disorders, shedding light on potential avenues for managing conditions such as premenstrual syndromes with mood symptoms.

In clinical practice, the World Health Organization's pain ladder serves as a cornerstone for pain management, advocating for a stepwise approach that incorporates adjuvant medications alongside traditional analgesics [14]. Among these adjuvants, certain antidepressants emerge as promising candidates, harnessing their dual functionality to alleviate both depression and pain. Amitriptyline, a prototypical tricyclic antidepressant, exemplifies this therapeutic synergy, exerting analgesic effects through inhibition of serotonin and noradrenaline reuptake [15].

Antidepressants are a beacon of hope for people suffering from mood disorders; they are hailed as innovations in psychiatric pharmacology. However, the efficacy of these medications in depression remains a subject of debate, given the heterogeneous nature of the disorder and the intricate interplay of biological and psychosocial factors. Despite their limitations, antidepressants play a pivotal role in restoring neurotransmitter balance within the brain, thereby alleviating mood disturbances and, increasingly recognized, attenuating pain perception.

This comprehensive review endeavors to explore the evolving landscape of antidepressant therapy in the context of pain management for patients with depressive disorders. By synthesizing empirical evidence and clinical insights, we aim to elucidate the complex interrelationships between depression and pain, shedding light on novel pharmacological strategies that hold promise for improving patient outcomes and advancing the field of psychiatric medicine.

Discussion

The analgesic effects of antidepressants in individuals with primary depressive disorders are selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) are nearly indistinguishable in individuals with primary depressive disorders. This implies that both classes of antidepressants can effectively alleviate pain in this population. There is the challenge of comparing the efficacy of tricyclic antidepressants (TCAs) with SSRIs and SSNRIs due to a lack of placebo-controlled trials for TCAs. It suggests that if non-placebo-controlled trials for TCAs were included, their results might be comparable to those of SSRIs and SSNRIs. Here's an observed positive association between the effects of antidepressant medication and the alleviation of pain. This suggests that as depressive symptoms improve with medication, pain symptoms also tend to decrease, indicating a close relationship between the two. There is a clarification that the findings are specific to individuals with primary depressive disorders and may not extend to those with primary pain illnesses. It underscores the need for further research specifically targeting patients with depression to better understand the impact of antidepressant medications on pain relief. Given the limitations and scope of the existing research, the statement emphasizes the necessity for more comprehensive studies comparing the effects of various types of antidepressant medications on pain in patients with depression. This implies that more research is necessary to improve treatment strategies for this population. Overall, the statement underscores the potential of SSRIs and SSNRIs in alleviating pain in individuals with primary depressive disorders while highlighting gaps in research and the need for more extensive studies in this area.

There are many unknown possibilities regarding the efficacy of antidepressants in treating pain disorders, emphasizing the necessity for further research. It suggests that demonstrating the essential role of these therapies in future pain disorder treatments is crucial. To achieve this, translation studies in both humans and animals are recommended, specifically designed to compare phenotypes with the recognized relationship between pain and depression and the intricate nature of this illness. Conducting such studies would enhance the existing knowledge base on this topic.

CONCLUSION

The review highlights that antidepressants possess antinociceptive effects in various chronic pain conditions. Therefore, practitioners should consider utilizing antidepressants as part of the treatment regimen for chronic pain, regardless of whether the patient also experiences depression. Given that there is stronger evidence supporting the efficacy of antidepressants in treating neuropathic pain compared to other types of pain, doctors should strive to differentiate between neuropathic and non-neuropathic pain when considering treatment options. This differentiation can help guide the choice of medication and optimize outcomes for patients. Antidepressant trials should be considered for patients experiencing "non-specific" pain, somatoform pain conditions, or purported psychogenic pain. This suggests that antidepressants may have a broader applicability beyond neuropathic pain and could potentially benefit patients with various pain presentations. Practitioners should also be mindful of tolerance levels when prescribing antidepressants for chronic pain management. Monitoring tolerance and adjusting treatment as necessary can help maintain effectiveness and minimize adverse effects over time. Overall, these implications underscore the potential role of antidepressants in managing chronic pain conditions and highlight the importance of a nuanced approach to treatment selection based on the specific characteristics of the pain experienced by each patient. Clinicians should be aware that selective serotonin reuptake inhibitors (SSRIs) may not exhibit as potent antinociceptive effects as other classes of antidepressants. Therefore, when selecting an antidepressant for chronic pain management, especially pain associated with depression, other classes of antidepressants might be more suitable. It's crucial for physicians to recognize that blood levels of antidepressants do not necessarily correlate with their effectiveness in relieving pain. Consequently, ordering specific dosages of antidepressants solely based on blood levels may not be justified, particularly if pain relief is the primary goal rather than targeting depression. If the primary symptom being targeted is pain rather than depression, clinicians

should consider increasing the antidepressant dosage to tolerance levels. This approach aims to optimize pain relief while minimizing adverse effects, irrespective of whether the patient reaches a predetermined therapeutic range for depression.

REFERENCES

1. 1. Koops, S., et al., *Speech as a biomarker for depression*. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2023. **22**(2): p. 152-160.
2. 2. Edwards, N., et al., *Prevalence of depression and anxiety in older people in low-and middle-income countries in Africa, Asia and South America: A systematic review and meta-analysis*. Journal of Affective Disorders, 2023. **325**: p. 656-674.
3. 3. de Castro, F., C. Cappa, and J. Madans, *Anxiety and depression signs among adolescents in 26 low-and Middle-Income Countries: prevalence and association with functional difficulties*. Journal of Adolescent Health, 2023. **72**(1): p. S79-S87.
4. 4. Allen, J.P., et al., *A social-development model of the evolution of depressive symptoms from age 13 to 30*. Development and Psychopathology, 2024. **36**(1): p. 280-290.
5. 5. Ignácio, Z., et al., *Epigenetic and epistatic interactions between serotonin transporter and brain-derived neurotrophic factor genetic polymorphism: insights in depression*. Neuroscience, 2014. **275**: p. 455-468.
6. 6. Bonilla-Jaime, H., et al., *Depression and Pain: Use of Antidepressants*. Curr Neuropharmacol, 2022. **20**(2): p. 384-402. DOI: 10.2174/1570159x19666210609161447.
7. 7. Dydyk, A. and T. Conermann, *Pain, chronic*. Treasure Island: StatPearls Publishing, 2020.
8. 8. Hooten, W.M. *Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment*. in *Mayo Clinic Proceedings*. 2016. Elsevier.
9. 9. Tang, N.K. and C. Crane, *Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links*. Psychological medicine, 2006. **36**(5): p. 575-586.
10. 10. Gebhardt, S., M. Heinzl-Gutenbrunner, and U. König, *Pain relief in depressive disorders: a meta-analysis of the effects of antidepressants*. Journal of Clinical Psychopharmacology, 2016. **36**(6): p. 658-668.
11. 11. Bekhuis, E., et al., *The network structure of major depressive disorder, generalized anxiety disorder and somatic symptomatology*. Psychological medicine, 2016. **46**(14): p. 2989-2998.
12. 12. Lisowska, A., K. Szwamel, and D. Kurpas, *Somatic symptoms and level of anxiety and depression in self-referral patients at the emergency department*. Medical Science Pulse, 2020. **14**(1): p. 21-30.
13. 13. Lewcun, B., et al., *Predicting suicidal ideation in adolescents with chronic amplified pain: The roles of depression and pain duration*. Psychological Services, 2018. **15**(3): p. 309.
14. 14. Kazdin, A.E., et al., *Antidepressant use in low-middle-and high-income countries: a World Mental Health Surveys report*. Psychological medicine, 2023. **53**(4): p. 1583-1591.
15. 15. Ashina, S., L. Bendtsen, and R. Jensen, *Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition*. Pain, 2004. **108**(1-2): p. 108-14. DOI: 10.1016/j.pain.2003.12.012.